Stock Price, News, Quote and Profile of IMMUNOPRECISE ANTIBODIES LTD(NASDAQ:IPA) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

IMMUNOPRECISE ANTIBODIES LTD

NASDAQ:IPA (5/14/2024, 3:30:02 PM)

After market: 1.15 -0.05 (-4.17%)

1.2

-0.06 (-4.76%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryLife Sciences Tools & Services

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap31.58M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The company is headquartered in Victoria, British Columbia and currently employs 102 full-time employees. The firm is a supplier of custom antibody discovery services. The firm offers species-agnostic advancements, such as the B cell Select single-cell interrogation technology, DeepDisplay custom phage libraries, as well as the Abthena bispecific program- platforms. The company leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its technologies in bio platform-based antibody discovery. The company offers a selection of antibodies, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma licensing for research purposes. Its services include specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners. The firm offers support to its partners, including rapid multi-omic analysis, customized project design, and others.

Company Info

IMMUNOPRECISE ANTIBODIES LTD

3204-4464 Markham St

Victoria BRITISH COLUMBIA

P: 12504830308

Employees: 102

Website: https://www.ipatherapeutics.com/

IPA News

2 months ago - ImmunoPrecise Antibodies Ltd.InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications

2 months ago - ImmunoPrecise Antibodies Ltd.IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments

2 months ago - InvestorPlaceIPA Stock Earnings: ImmunoPrecise Antibodies Misses EPS, Beats Revenue for Q3 2024

IPA stock results show that ImmunoPrecise Antibodies missed analyst estimates for earnings per share but beat on revenue for the third quarter of 2024.